Back to discover
Disease
Non-Muscle Invasive Bladder Neoplasms
Late-stage therapeutic developmentEmerging research
1
Publications
5
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Advances in diagnosis and treatment of bladder cancer.
Research2024-02-12BMJ (Clinical research ed.)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
- Q1 2028Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
- Q2 2028A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
- Q4 203017000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
- Q3 2031A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20302026-07-07
Upcoming trial readoutHigh impact
Results expected Q2 20282026-07-06
Clinical MilestonesViewHide
Results expected
- 2026-07-0717000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-06A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR AlterationsResults expected Q2 2028
- 2026-07-02A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)Results expected Q3 2031
- 2026-06-05Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder CancerResults expected Q1 2028
- 2026-04-15A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder CancerResults expected Q1 2027
Activity timeline5
- 2026-07-07Clinical17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-06ClinicalA Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR AlterationsResults expected Q2 2028
- 2026-07-02ClinicalA Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)Results expected Q3 2031
- 2026-06-05ClinicalPhase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder CancerResults expected Q1 2028
- 2026-04-15ClinicalA Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder CancerResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
5
5
2
0
Late-stage studies
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes2
- Non-Muscle Invasive Bladder Neoplasms1
- Urinary Bladder Neoplasms1
Leading journals1
- BMJ (Clinical research ed.)1
Leading researchers4
- Cheng L1
- Cookson MS1
- Guercio BJ1
- Lopez-Beltran A1
Affiliations (unnormalised)6
- Brown University.1
- Department of Pathology and Laboratory Medicine1
- James P. Wilmot Cancer Institute1
- Legorreta Cancer Center1
- University of Cordoba Medical School1
- University of Oklahoma Health Sciences Center and the Stephenson Cancer Center1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A urothelial carcinoma found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.